Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Advanced Neuroendocrine Neoplasms
NCT07272512Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib in neuroendocrine neoplasms (NENs), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-Free Survival at 12 months. Started Nov 2025; status: recruiting.
02
Drugs
surufatinib
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT07272512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272512.